Riskpilot← Back to searchSign inGet full accessInstagraft AB
ABActiveOrg 5590495817Sunnorpsgatan 5Research and experimental development on natural sciences and engineering · NACE 7210Est. 20160 employees
Revenue 2024
SEK 118K
EBITDA margin
-24.6%
-2% vs 2023
Equity ratio
36.7%
Financial strength
Net profit 2024
SEK -30K
+15% vs 2023
| Revenue | SEK 118K | — |
| EBITDA | SEK -29K | -2% |
| Net profit | SEK -30K | +15% |
| Total assets | SEK 267K | +9% |
| Equity | SEK 98K | -23% |
| Employees | 0 | — |
Legal name
Instagraft AB
Org number
5590495817
Legal form
Aktiebolag
NACE code
7210 · Research and experimental development on natural sciences and engineering
Founded
2 februari 2016
Share capital
SEK 50 000
Employees
0
VAT registered
Yes
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen Firman tecknas var för sig av ledamöterna
Company purpose
Företaget skall verka för tillverkning, utveckling, import, export, marknadsföring och försäljning av medicintekniska produkter, kosmetika och läkemedel, samt utföra konsultuppdrag och handel med värdepapper.
Address
Sunnorpsgatan 5
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Revenue | 111 | 0 | 0 | 0 | 118 |
| Staff expenses | — | — | — | — | — |
| EBITDA | −111 | −10 | −4 | −28 | −29 |
| Depreciation & amort. | −15 | −15 | −15 | −7 | −0 |
| EBIT | −126 | −25 | −19 | −35 | −29 |
| Net financials | — | −60 | — | — | −1 |
| Profit before tax | −126 | −85 | −19 | −35 | −30 |
| Tax | −0 | −0 | — | — | −0 |
| Net profit | −126 | −85 | −19 | −35 | −30 |
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Total assets | 561 | 331 | 309 | 246 | 267 |
| Equity | 267 | 182 | 163 | 128 | 98 |
| Long-term debt | 0 | 0 | — | — | 0 |
| Short-term debt | 294 | 149 | 145 | 118 | 169 |
| Total debt | 294 | 149 | 145 | 118 | 169 |
EBITDA margin
-24.6%
This company
15.8%
Market median
-256% vs market
20202024
Equity ratio
36.7%
This company
38.2%
Market median
+4% vs market
20202024
Return on equity
-30.6%
This company
18.4%
Market median
-266% vs market
20202024
Net profit margin
-25.4%
This company
8.1%
Market median
-414% vs market
20202024
Asset turnover
0.44×
This company
1.12×
Market median
-61% vs market
20202024
Debt / equity
1.72×
This company
0.62×
Market median
-177% vs market
20202024
- Annual report 2024Filed via Bolagsverket / SCB · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Bolagsverket / SCB · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Bolagsverket / SCB · Period 2020-01-01 – 2020-12-31
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
IP Chief Executive Officer | Chief Executive Officer | 2022 |
| Name | Role | Member since |
|---|---|---|
| Current (2) | ||
| Board of Directors | 2022 | |
| Chairman | 2022 | |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
| Company | 100% | 100% | 0001 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
S2Medical AB (publ)
Instagraft AB Board members of Instagraft AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Inge Petter Sivlér | Chief Executive Officer | 0 companies |
| Göran Fredrik Skog | Board of Directors | 0 companies |
| Carl Mårten Andreas Skog | Chairman | 0 companies |